Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.2 USD | +0.75% | +17.53% | 0.00% |
May. 14 | Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target | MT |
May. 09 | CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 2B | |
+42.28% | 50.93B | |
-0.51% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+13.51% | 26.02B | |
-22.08% | 18.9B | |
+7.44% | 13.21B | |
+24.03% | 12.17B | |
+30.19% | 12.16B |
- Stock Market
- Equities
- CGON Stock
- News CG Oncology, Inc.
- Cantor Fitzgerald Starts Coverage on CG Oncology With Overweight Rating, $75 Price Target